Skip to main content
Signal8
Launch Terminal

ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Arrowhead Pharmaceuticals, Inc., founded in 1989 and based in Pasadena, California, is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for complex and challenging-to-treat diseases within the United States. The company's extensive therapeutic pipeline primarily leverages RNA interference (RNAi) technology. Among its advanced clinical programs are: ARO-AAT, a Phase II therapeutic targeting liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is undergoing both Phase 2b and Phase 3 clinical evaluations for hypertriglyceridemia; ARO-ANG3, currently in Phase 2b development to reduce the production of angiopoietin-like protein 3; and ARO-HIF2, a Phase 1b candidate designed to treat clear cell renal cell carcinoma. Arrowhead also has several compounds in earlier clinical development, including ARO-HSD in Phase 1/2a for other liver diseases, ARO-ENaC in Phase 1/2a, aimed at decreasing the epithelial sodium channel alpha subunit in lung airways, and ARO-C3, also in Phase 1/2a, for complement-mediated diseases. Further expanding its diverse portfolio, the company is actively developing ARO-Lung2 for chronic obstructive pulmonary disorder (COPD), ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-XDH for uncontrolled gout, and ARO-COV for COVID-19 and other pulmonary-borne pathogens. Beyond its core internal programs, Arrowhead is involved in the progression of JNJ-3989, a subcutaneously administered RNAi therapeutic for chronic hepatitis B virus infection; Olpasiran, intended to reduce apolipoprotein A production; and ARO-AMG1, which targets genetically validated cardiovascular pathways. Strategic collaborations are integral to Arrowhead's development efforts. The company holds a licensing and research agreement with Janssen Pharmaceuticals, Inc. for the co-development of ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3, all RNAi therapeutics focused on liver-expressed targets. Additionally, Arrowhead has a licensing and research partnership with Takeda Pharmaceuticals U.S.A., Inc. to develop an RNAi therapeutic candidate specifically for liver disease.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWRHealthcare
-0.98%$59.90
AH$59.75-0.25%vs close
Mkt Cap$8.46B
Float135.7M
O/S141.25M
Vol
$ Vol
RVOL
Inst Own84.4%
Earnings
Dilution
Arrowhead Pharmaceuticals, Inc. logoNASDAQ:ARWR$59.90-0.98%
Phase Distribution
54 lead-sponsored trials·11 active·27 completed
Phase 113
Phase 1/211
Phase 217
Phase 38
Not applicable5
(6 more as collaborator)
Status Overview
Not yet recruiting1
Recruiting7
Active, not recruiting4
Completed27
Stopped14
Expanded access1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Completed

    Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)

    Plozasiran, Placebo

    Familial Chylomicronemia

    Enrollment
    75
    Start
    Dec 2021
    Primary Completion
    Apr 2024
    Completion
    Apr 2026
    NCT05089084
  • Phase 3
    Completed

    Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

    Plozasiran Injection, Placebo

    Severe Hypertriglyceridemia

    Enrollment
    446
    Start
    Jul 2024
    Primary Completion
    Jun 2026
    Completion
    Aug 2026
    NCT06347003
  • Phase 3
    Completed

    Study of Plozasiran in Adults With Severe Hypertriglyceridemia

    Plozasiran Injection, Placebo

    Severe Hypertriglyceridemia

    Enrollment
    311
    Start
    Jul 2024
    Primary Completion
    Jun 2026
    Completion
    Sep 2026
    NCT06347016
  • Phase 3
    Completed

    Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

    Plozasiran Injection, Placebo

    Hypertriglyceridemia

    Enrollment
    1,456
    Start
    May 2024
    Primary Completion
    Jun 2026
    Completion
    Sep 2026
    NCT06347133
  • Phase 3
    Active, not recruiting

    Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia

    Plozasiran Injection

    Hypertriglyceridemia

    Enrollment
    710
    Start
    Apr 2025
    Primary Completion
    Jul 2028est.
    Completion
    Jul 2028est.
    NCT06822790
  • Phase 3
    Recruiting

    Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis

    Plozasiran, Placebo

    Severe Hypertriglyceridemia

    Enrollment
    288
    Start
    Apr 2025
    Primary Completion
    Mar 2029est.
    Completion
    Jun 2029est.
    NCT06880770
  • Phase 3
    Active, not recruiting

    A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

    zodasiran Injection, Placebo

    Homozygous Familial Hypercholesterolemia

    Enrollment
    70
    Start
    Jun 2025
    Primary Completion
    Aug 2027est.
    Completion
    Aug 2027est.
    NCT07037771
  • Phase 3
    Recruiting

    Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia

    Zodasiran

    Homozygous Familial Hypercholesterolemia

    Enrollment
    10
    Start
    Oct 2026est.
    Primary Completion
    Jul 2028est.
    Completion
    Aug 2028est.
    NCT07473843
  • Phase 2
    Terminated

    A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection

    ARC-520, Placebo

    Hepatitis B, Chronic

    Enrollment
    58
    Start
    Mar 2014
    Primary Completion
    Jan 2017
    Completion
    Jan 2017
    NCT02065336
  • Phase 2
    Withdrawn

    Study of ARC-520 in Patient With Chronic Hepatitis B Virus

    ARC-520 Injection

    Chronic Hepatitis B

    Enrollment
    0
    Start
    Feb 2015
    Primary Completion
    Dec 2015est.
    Completion
    Mar 2016est.
    NCT02349126
  • Phase 2
    Terminated

    Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

    ARC-520, Placebo

    Chronic Hepatitis B

    Enrollment
    4
    Start
    Aug 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02452528
  • Phase 2
    Terminated

    Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)

    ARC-520, entecavir

    Hepatitis B, Hepatitis D

    Enrollment
    79
    Start
    Dec 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02577029
  • Phase 2
    Terminated

    A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection

    ARC-520 Injection, entecavir

    Hepatitis B

    Enrollment
    58
    Start
    Sep 2015
    Primary Completion
    Jan 2017
    Completion
    Jan 2017
    NCT02604199
  • Phase 2
    Terminated

    A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection

    ARC-520, entecavir

    Hepatitis B

    Enrollment
    32
    Start
    Nov 2015
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02604212
  • Phase 2
    Terminated

    Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection

    ARC-520 Injection, entecavir

    Hepatitis B

    Enrollment
    12
    Start
    Mar 2016
    Primary Completion
    Dec 2016
    Completion
    Dec 2016
    NCT02738008
  • Phase 2
    Withdrawn

    Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels

    ARC-AAT Injection

    Alpha-1 Antitrypsin Deficiency

    Enrollment
    0
    Start
    Oct 2016est.
    Primary Completion
    Nov 2016
    Completion
    Nov 2016
    NCT02900183
  • Phase 2
    Completed

    Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

    Fazisiran Injection

    Alpha 1-Antitrypsin Deficiency

    Enrollment
    40
    Start
    Aug 2019
    Primary Completion
    Nov 2021
    Completion
    Sep 2023
    NCT03945292
  • Phase 2
    Completed

    Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD)

    ARO-AAT

    Alpha 1-Antitrypsin Deficiency

    Enrollment
    16
    Start
    Oct 2019
    Primary Completion
    Apr 2022
    Completion
    Dec 2023
    NCT03946449
  • Phase 2
    Completed

    Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia

    ARO-APOC3, Placebo

    Severe Hypertriglyceridemia

    Enrollment
    229
    Start
    May 2021
    Primary Completion
    Mar 2023
    Completion
    Aug 2023
    NCT04720534
  • Phase 2
    Completed

    Study of ARO-ANG3 in Adults With Mixed Dyslipidemia

    ARO-ANG3, Placebo

    Mixed Dyslipidemia

    Enrollment
    204
    Start
    Jun 2021
    Primary Completion
    Aug 2022
    Completion
    Sep 2024
    NCT04832971
  • Phase 2
    Completed

    Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia

    ARO-APOC3, Placebo

    Mixed Dyslipidemia

    Enrollment
    353
    Start
    Sep 2021
    Primary Completion
    Feb 2023
    Completion
    Aug 2023
    NCT04998201
  • Phase 2
    Terminated

    Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)

    ARO-ANG 3 Injection

    Homozygous Familial Hypercholesterolemia

    Enrollment
    18
    Start
    Apr 2022
    Primary Completion
    May 2023
    Completion
    Nov 2025
    NCT05217667
  • Phase 2
    Completed

    Study of ARO-APOC3 in Adults With Dyslipidemia

    ARO-APOC3

    Dyslipidemias

    Enrollment
    418
    Start
    Jul 2022
    Primary Completion
    Sep 2025
    Completion
    Sep 2025
    NCT05413135
  • Phase 2
    Recruiting

    Study of Inhaled ARO-RAGE in Allergen-induced Mild Asthma

    ARO-RAGE, Placebo

    Asthma

    Enrollment
    36
    Start
    Mar 2026
    Primary Completion
    Dec 2027est.
    Completion
    Apr 2028est.
    NCT07241546
  • Phase 2
    Not yet recruiting

    A Trial to Evaluate the Efficacy and Safety of ARO-INHBE in Adults With Metabolic Dysfunction-Associated Steatohepatitis

    ARO-INHBE, Placebo

    Metabolic Dysfunction-Associated Steatohepatitis

    Enrollment
    252
    Start
    Sep 2026est.
    Primary Completion
    Oct 2029est.
    Completion
    Oct 2029est.
    NCT07859813

1-25 of 54

Search ClinicalTrials.gov for “Arrowhead Pharmaceuticals”